NGS-Based Genetic Analysis in a Cohort of Italian Patients with Suspected Inherited Myopathies and/or HyperCKemia

Genes (Basel). 2023 Jul 2;14(7):1393. doi: 10.3390/genes14071393.

Abstract

Introduction/Aims HyperCKemia is considered a hallmark of neuromuscular diseases. It can be either isolated or associated with cramps, myalgia, weakness, myoglobinuria, or rhabdomyolysis, suggesting a metabolic myopathy. The aim of this work was to investigate possible genetic causes in order to help diagnose patients with recurrent hyperCKemia or clinical suspicion of inherited metabolic myopathy. Methods A cohort of 139 patients (90 adults and 49 children) was analyzed using a custom panel containing 54 genes associated with hyperCKemia. Results A definite genetic diagnosis was obtained in 15.1% of cases, while candidate variants or variants of uncertain significance were found in a further 39.5%. Similar percentages were obtained in patients with infantile or adult onset, with some different causative genes. RYR1 was the gene most frequently identified, either with single or compound heterozygous variants, while ETFDH variants were the most common cause for recessive cases. In one patient, mRNA analysis allowed identifying a large LPIN1 deletion missed by DNA sequencing, leading to a certain diagnosis. Conclusion These data confirm the high genetic heterogeneity of hyperCKemia and metabolic myopathies. The reduced diagnostic yield suggests the existence of additional genes associated with this condition but also allows speculation that a significant number of cases presenting with hyperCKemia or muscle symptoms are due to extrinsic, not genetic, factors.

Keywords: Next Generation Sequencing (NGS); creatine kinase; hyperCKemia; myoglobinuria; rhabdomyolysis; skeletal muscle damage.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Child
  • Humans
  • Muscles
  • Muscular Diseases* / diagnosis
  • Muscular Diseases* / genetics
  • Myalgia / complications
  • Myalgia / genetics
  • Neuromuscular Diseases* / genetics
  • Phosphatidate Phosphatase
  • Rhabdomyolysis* / complications
  • Rhabdomyolysis* / genetics

Substances

  • LPIN1 protein, human
  • Phosphatidate Phosphatase

Grants and funding

This research was funded by the University of Milan (PSR2017_DIP_009_Ghezzi), the European Joint Programme on Rare Diseases (EJP RD) project GENOMIT (Italian Ministry of Health ERP-2019–23671045), the Mariani Foundation (CM23), the Italian Ministry of Health (RCC). This work was promoted within the European Reference Network (ERN) for Rare Neuromuscular Diseases: C.L., D.G., A.A., I.M., and G.P.C. are members of the ERN EURO-NMD. We thank the Associazione Centro Dino Ferrari for its support.